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PATIENT-REPORTED OUTCOME (PRO) LABELING CLAIMS IN PAIN 
TREATMENT: OVERVIEW OF US AND EUROPEAN DRUG APPROVALS
Caron M1, Emery MP1, Marquis P2, Piault E2, Scott JA3
1MAPI Research Trust, Lyon, France, 2Mapi Values, Boston, MA, USA, 3Mapi Values, 
Macclesﬁ eld, Cheshire, UK
OBJECTIVES: To review the PRO end-points appearing in the product labels of pain 
treatments with a particular focus on products approved both in the United States 
(US) and in Europe. METHODS: Pain treatments approved in the US since 1998 and
in Europe through the centralized procedure established in 1995, and including PRO 
evaluations in the approved labeling were identiﬁ ed from the PROLabels database. 
PROLabels is a unique on-line tool providing information on the products for which
the FDA and/or the EMEA have granted PRO labeling claims. For the products 
approved by both agencies, we will compare the PRO endpoints appearing in the
approved labeling and also analyze the PRO studies submitted by the sponsor. 
RESULTS: Overall, 26 products indicated for the treatment of pain were identiﬁ ed,
accounting for 16 different molecules and ten different indications. Various methods
were used to measure pain (VAS, Likert scales). Of these 26 drugs, only two showed
evidence of treatment efﬁ cacy using additional PRO endpoints (function and patient
satisfaction). The PRO appearing in the approved labeling are rather consistent
between both regulatory agencies. Information on additional PRO endpoints that were 
assessed in the clinical studies submitted by the sponsors but were not accepted in the 
approved labeling was available for nine out of the 26 dossiers. The concepts assessed 
were health-related quality of life, psychological functioning, physical functioning 
(including interference with sleep) and patient global impression. A focus was made 
on the different reasons of rejection of the most recent claims, in the light of the current 
PRO guidances published by both regulatory agencies. CONCLUSIONS: Overall, 
only a few pain treatments include other PRO endpoints in addition to pain in their
labeling. An interesting ﬁ nding is the similarity between the American and the 
European PRO claims for pain therapies.
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USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN
PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
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OBJECTIVES: This analysis examines the impact of ustekinumab on symptoms com-
monly associated with moderate-to-severe psoriasis, including itch, bodily pain, and
fatigue, using data from a Phase 3 clinical trial. METHODS: In PHOENIX I trial, 
766 patients were randomized to ustekinumab 45 mg or 90 mg at weeks 0 and 4 and 
every 12 weeks thereafter, or placebo at weeks 0 and 4 with crossover to ustekinumab
at week 12. Assessments included the Itch visual analogue scale (VAS) (0 [no itch] to 
10 [severe itch]) and for pain and fatigue the SF-36 bodily pain and vitality scales (0 
to 100 [higher scores indicate greater impact of pain and fatigue on quality of life]). 
RESULTS: At baseline, mean (SD) itch score was 6.8 (2.7), and mean (SD) bodily pain 
and vitality scores were 45.5 (11.4) and 49.7 (10.0), respectively. At week 12, average 
change in itch score from baseline was –4.9, 5.1, and –0.8 in the ustekinumab 45 mg, 
90 mg, and placebo group, respectively, representing a median reduction of 86% in
itch in the ustekinumab-treated patients compared to a 4% reduction in placebo-
treated patients (p  0.001 for each ustekinumab group vs. placebo). Mean change in 
pain score from baseline to week 12 was 4.4, 5.8, and 0.2 in the ustekinumab 45 mg, 
90 mg, and placebo group, respectively (p  0.005 for each ustekinumab group vs. 
placebo). Speciﬁ cally, 37% of patients reported moderate or more severe bodily pain 
at baseline. At week 12, 17% of ustekinumab-treated patients vs. 38% of placebo-
treated patients reported moderate or severe bodily pain (p  0.01). Similarly,
ustekinumab-treated patients demonstrated a greater improvement in vitality score 
(1.5 in the ustekinumab 45 mg group and 1.6 in the 90 mg group) than the placebo
group (1.6) (p  0.005 for each ustekinumab group vs. placebo). CONCLUSIONS:
Ustekinumab improves itch, pain, and fatigue in patients with moderate-to-severe
psoriasis.
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USE OF PRESCRIPTION PHARMACOTHERAPY IN PATIENTS WITH
FIBROMYALGIA : EVIDENCE OF UNMET NEEDS?
Berger A1, Oster G1, Juday T2, Blum S2, Erder MH2
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA
OBJECTIVES: Fibromyalgia (FM) is a chronic disorder characterized by multiple 
symptoms (e.g., pain, fatigue, cognitive dysfunction, sleep disturbance). The efﬁ cacy 
of most medications currently used to treat FM is limited, however, and problems of 
tolerability are often encountered, possibly causing many patients to discontinue 
therapy. This study examines patterns of use of prescription (Rx) medications with an
eye toward assessing possible unmet clinical need. METHODS: Using a large US
health insurance database spanning the period 2005–2007, we identiﬁ ed all patients
with q1 medical encounters for FM (deﬁ ned as ICD-9-CM diagnosis code 729.1) in 
each of these three calendar years (“FM patients”). Rx medications possibly related
to the treatment of FM (“FM-related”) were deﬁ ned to include antiepileptics, benzo-
diazepines, nonsteroidal anti-inﬂ ammatory drugs, muscle relaxants, sedatives/hypnot-
ics, opioids, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake
inhibitors, L-dopa, and carbidopa. We examined receipt of FM-related Rx medications
from two alternative perspectives: (1) period prevalence (receipt anytime during each 
calendar year); and (2) point prevalence (evidence of use on July 1 of each calendar
year). Substantial differences between period prevalence and point prevalence rates
may be suggestive of high rates of medication discontinuation. RESULTS: A total of 
51,885 patients met all study entry criteria. In each of the three years, approximately
two-thirds of study subjects had evidence of receipt of FM-related Rx medications 
(65.2% in 2005, 66.5% in 2006, 66.7% in 2007). Corresponding point prevalence 
estimates, however, were substantially lower (July 1, 2005: 38.1%; July 1, 2006: 
40.9%; July 1, 2007: 41.3%). CONCLUSIONS: While roughly two-thirds of FM 
patients received FM-related Rx medications in any given year, point prevalence esti-
mates were substantially lower, potentially suggestive of high rates of medication dis-
continuation. Further research is needed to better understand the extent to which these 
treatment patterns are indicative of unmet medical need with currently available Rx
medications in patients with FM.
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USE OF POLYPHARMACY IN PATIENTS WITH FIBROMYALGIA
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OBJECTIVES: Fibromyalgia (FM), a chronic disorder characterized by multiple symp-
toms (e.g., pain, fatigue, cognitive dysfunction, sleep disturbance), is difﬁ cult to treat.
This study examined the extent to which FM patients in the US receive multiple pre-
scription (Rx) drugs to treat their condition (“polypharmacy”). METHODS: Using a 
large US health insurance database spanning a three-year period (January 1, 2005 to 
December 31, 2007), we identiﬁ ed all patients with q1 medical encounters for FM
(deﬁ ned as ICD-9-CM code 729.1) in each of these three calendar years (“FM 
patients”). Rx medications designated as possibly related to the treatment of FM
(“FM-related”) included antiepileptics, benzodiazepines, nonsteroidal anti-inﬂ amma-
tory drugs (NSAIDs), muscle relaxants, sedatives/hypnotics, opioids, selected antide-
pressants (e.g., tricyclics, serotonin-norepinephrine reuptake inhibitors, selective
serotonin reuptake inhibitors), L-dopa, and carbidopa. Polypharmacy, which was 
deﬁ ned as receipt of q2 FM-related Rx drugs, was assessed from two alternative per-
spectives: 1) period-prevalence (receipt anytime during each calendar year), and 2) 
point-prevalence (evidence of use on July 1 of each calendar year). RESULTS: A total
of 51,885 patients met all study entry criteria, of whom 33,831, 34,484, and 34,616
received FM-related Rx drugs in calendar years 2005, 2006, and 2007, respectively. 
The most commonly received Rx drugs were opioids, antidepressants, and NSAIDs.
Among patients receiving FM-related Rx drugs, approximately 80% had evidence of 
receipt of q2 such medications in any given year; about 60% had evidence of receipt
of 3 or more. Corresponding point-prevalence rates (on July 1 of each year) were
approximately 61% and 36%, respectively. Commonly used combinations of Rx drugs 
included antidepressants and opioids, antiepileptics and antidepressants, and antiepi-
leptics, antidepressants, and opioids. CONCLUSIONS: Polypharmacy in the treat-
ment of FM is widespread, suggesting that the symptoms of relatively few patients are
well managed with any single currently available Rx drug.
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CURTAILING LAB-TEST ORDERING IN A MANAGED CARE SETTING
THROUGH REDESIGN OF A COMPUTERIZED ORDER-FORM
Kahan NR, Waitman DA, Vardy DA
Leumit Health Fund, Tel-Aviv, Israel
OBJECTIVES: Although laboratory testing is essential for the diagnosis, pharmaco-
therapy, and monitoring of anemia, inefﬁ cient utilization of laboratory resources may 
increase the cost-of-treatment of anemia without improving clinical outcomes. Of 
particular concern is the ordering of redundant tests incapable of providing important 
information for treatment when clinically signiﬁ cant changes in biochemical outcomes 
do not occur over short periods of time. Bundling of tests into diagnostic categories
on order forms may cause such overutilization. The objective of this study was to 
determine whether unbundling of order-sets on a computerized order-form can reduce 
the number of suspected unnecessary blood tests for folic acid and vitamin B-12
ordered by primary care physicians in a managed care organization in Israel. 
METHODS: This study was conducted in the Leumit Health Fund of Israel that 
provides medical coverage to ~700,000 members nationally. A new version of a com-
puterized order form was launched. Utilization patterns were calculated for tests for 
vitamin B-12, folic acid and ferritin which were previously bundled together under a 
collective diagnostic classiﬁ cation category labeled “Anemia” and now appearing 
separately. Concomitant utilization patterns for tests for hemoglobin and iron were 
evaluated as controls. RESULTS: Tests ordered for the three target tests decreased by 
31%-41% relative to the preintervention month, with a further decrease to 36%-53% 
the following month. Negligible changes in utilization patterns were observed for 
the controls (-2%-3%) during the post-intervention period. CONCLUSIONS:
Restructuring of a computerized order-form signiﬁ cantly reduced the number of lab 
tests suspected of being unnecessary or redundant. We cannot rule out that some 
patients with folate deﬁ ciency may not have been identiﬁ ed after unbundling the tests 
due to the additional inconvenience caused to physicians who now had to order tests 
separately. When over-utilization of laboratory resources is suspected, restructuring of 
ordering procedures should be considered prior to implementing resource-intensive 
interventions.
